Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217971 · ClinicalTrials.gov registry record · Phase 2
Dronabinol Treatment for Marijuana Addiction
A Phase 2 study of Marijuana Abuse, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT00217971 is a Phase 2 study of Marijuana Abuse that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 156 participants, above the 60-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (160% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00217971, a Phase 2 study of Marijuana Abuse, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dronabinol
Study Locations (1)
New York
- Research Foundation for Mental Hygiene, Inc. - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217971
The ClinicalTrials.gov registry entry for NCT00217971 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 60-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (160% higher). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marijuana Abuse appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00217971 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00217971 about?
NCT00217971 is a clinical study titled "Dronabinol Treatment for Marijuana Addiction". The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.
What is the current status of trial NCT00217971?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2005-03. Estimated completion is 2009-12.
What conditions does trial NCT00217971 study?
This clinical trial studies the following conditions: Marijuana Abuse.
What interventions are being tested in trial NCT00217971?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG).
Who is sponsoring clinical trial NCT00217971?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00217971 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
COMPLETED · Phase 2
-
Therapeutic Substance Abuse Treatment in Pregnancy - 1
COMPLETED · Phase 2
-
Effects of Cannabidiol on Marijuana-seeking in Humans
COMPLETED
-
Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.